Compass Pathways reports COMP006 Part B 26-week results for COMP360, reinforcing rapid onset and durable relief in treatment-resistant depression across nearly 600 patients. A 39% MADRS ≥25% response at week 6 and retreatment-associated remission support a potential new standard of care, with rolling NDA submission on track for final submission in Q4 2026 and a possible 1H 2027 launch pending regulatory approval.
A White House order accelerates psychedelic research and grants priority review vouchers, boosting CMPS prospects. While validation helps COMP360, safety concerns and FDA design issues remain headwinds. Compass Pathways appears positioned for a faster review trajectory, but near-term upside depends on FDA acceptance and trial outcomes across psychedelics.
Compass Pathways (CMPS) announced that its psilocybin-based therapy for depression successfully met the main goal in a late-stage clinical trial. This milestone could enhance investor confidence and stimulate positive market sentiment toward CMPS in the near term.
CMPS shares declined 24.4% to $3.50 in pre-market trading. Compass Pathways achieved primary endpoint in Phase 3 trial for treatment-resistant depression. Despite trial success, CMPS experienced a significant pre-market drop. Overall market mixed with Nasdaq futures up by 0.1% today.
